Presenilin-2 (PSEN2)¹¹ Presenilin-2 (PSEN2)
Encoded by the PSEN2 gene on chromosome 1q42.13; forms the catalytic aspartyl protease subunit of the gamma-secretase complex alongside presenilin-1, nicastrin, APH-1, and PEN-2 is one of three genes — alongside PSEN1 and APP — in which pathogenic mutations cause familial early-onset Alzheimer's disease (FAD). PSEN2 mutations are the rarest of the three causes (<5% of all early-onset familial cases) and are distinguished from their PSEN1 counterparts by later onset, broader age variability, and documented incomplete penetrance: not every carrier develops the disease.

The M239I mutation (c.717G>A; p.Met239Ile) substitutes methionine for isoleucine at position 239 of the mature PSEN2 protein. It was first described in 2000 in an Italian pedigree with autopsy-confirmed Alzheimer's disease and has subsequently been identified in multiple European families. The same methionine at position 239 is the site of the related M239V mutation (rs28936379), originally discovered in Volga German families in the original 1995 characterization of PSEN2 — making this codon a recognized hotspot for dominant pathogenic substitutions.

The Mechanism

Methionine 239 sits within transmembrane domain 5 of PSEN2, near the active site of the gamma-secretase complex²² gamma-secretase complex
The four-protein complex that cleaves type I transmembrane proteins within the lipid bilayer; its principal substrates relevant to Alzheimer's disease are the amyloid precursor protein (APP) and Notch. In normal APP processing, gamma-secretase cleaves APP to generate a mixture of Aβ peptides, predominantly the shorter Aβ40 form. The M239I substitution alters the geometry of the active-site pore, shifting the cleavage pattern toward production of the longer Aβ42 and Aβ43 peptides — forms that are far more prone to aggregation and amyloid plaque seeding. Published data from the AlzForum mutations database document that M239I produces decreased Aβ40/Aβ42 ratios and altered Aβ(37+38+40)/(42+43) ratios, consistent with this cleavage shift.

Beyond amyloid production, PSEN2 M239I disrupts calcium homeostasis in the endoplasmic reticulum (ER). Zatti et al. 2004³³ Zatti et al. 2004
Patient fibroblasts and engineered HEK293 cells expressing M239I showed significantly reduced Ca2+ release from ER stores compared to controls; capacitative calcium entry was unaffected, indicating specific impairment of store-filling rather than store-refilling. Neurobiol Dis. demonstrated that this ER calcium depletion is a direct consequence of the mutation. A follow-up study confirmed that M239I and related PSEN2 mutations reduce calcium content in both the ER and the Golgi apparatus⁴⁴ both the ER and the Golgi apparatus
This challenges the earlier "calcium overload" model of presenilin pathogenicity; instead, intracellular store depletion may impair neuronal signaling, energy metabolism, and protein processing in ways that promote neurodegeneration independently of amyloid.

Additionally, PSEN2 M239I alters trafficking of cystatin C — a neuroprotective secreted protein — in mouse primary neurons, reducing secretion of its glycosylated form and potentially diminishing the neuroprotective extracellular pool.

The Evidence

The clinical characterization comes primarily from two Italian research groups with access to the original and subsequent pedigrees. Finckh et al. 2000⁵⁵ Finckh et al. 2000
Neurology; Italian family with autopsy-confirmed AD; proband and affected relatives showed onset 44–58 years; two mutation carriers at ages 58 and 68 were cognitively unaffected at the time of examination, providing direct evidence of incomplete penetrance established the key clinical signature of this mutation: onset spanning the fifth and sixth decade, and a demonstrable rate of incomplete penetrance — in the family reported, 5 siblings carried the mutation, 3 developed AD and 2 did not.

A later case report by Testi et al. 2012⁶⁶ Testi et al. 2012
J Alzheimers Dis; characterized a PSEN2 M239I carrier with early frontal lobe hypoperfusion on SPECT imaging; clinical features included severe executive dysfunction, myoclonic tremor, and memory loss — confirming pathogenicity and illustrating the phenotypic heterogeneity, including potential atypical presentations extended the phenotypic picture, confirming the mutation's pathogenicity while documenting atypical presentations including early frontal involvement — a pattern not always seen in sporadic AD.

The key distinguishing feature from PSEN1 mutations is penetrance. PSEN1 mutations produce near-100% penetrance with onset reliably before age 60–65. PSEN2 mutations — including M239I — can skip generations or remain clinically silent past age 70 in some carriers. This creates genuine counseling uncertainty: a confirmed carrier faces substantial but not certain lifetime risk, and the age by which risk substantially accumulates spans four decades.

Practical Actions

For confirmed heterozygous carriers (AG genotype), the primary clinical needs are cognitive monitoring and genetic counseling for the family. Sporadic Alzheimer's prevention trials — including the A4 Study, AHEAD 3-45, and the DIAN-TU program — specifically seek to enroll pre-symptomatic carriers of high-penetrance FAD mutations including PSEN2 variants; enrollment provides access to experimental anti-amyloid interventions (lecanemab, donanemab) currently unavailable outside trials.

The monitoring goal is detecting cognitive change early — specifically mild cognitive impairment (MCI) — because cognitive reserve strategies and trial-based interventions are most effective in the pre-symptomatic or very early symptomatic window. Neurological review every 1–2 years, with neuropsychological testing covering episodic memory, executive function, and language, is appropriate for pre-symptomatic carriers in their 40s and beyond.

Interactions

The most clinically relevant interaction is with APOE genotype. While the Finckh 2000 paper specifically reported no influence of APOE genotype on phenotype in their family, this finding was based on a small pedigree and does not preclude population-level modulation. The APOE ε4 allele (rs429358) accelerates onset and increases severity in sporadic AD and in other FAD mutations; this interaction is plausible but not directly established for PSEN2 M239I specifically.

The homologous mutation at the same codon in PSEN1 — M233V (rs63751287) — produces a far more severe phenotype with onset in the mid-20s and near-100% penetrance, demonstrating how the same amino acid change in the two paralogue subunits of gamma-secretase produces profoundly different clinical trajectories.

The liver makes a continuous choice: phosphorylate incoming glucose (clearing it from the bloodstream) or conserve it. The enzyme doing the phosphorylating is glucokinase (GCK), and its gatekeeper is glucokinase regulatory protein (GKRP)¹¹ glucokinase regulatory protein (GKRP)
Encoded by the GCKR gene on chromosome 2; shuttles glucokinase in and out of the nucleus in response to fasting and fed-state signals, acting as the liver's primary brake on glucose uptake. rs780095 sits inside an intron of GCKR at a liver-specific enhancer element — a genomic switch that determines how much GKRP protein the liver produces.

This variant is mechanistically distinct from the better-characterized GCKR coding variant rs1260326 (P446L), which impairs GKRP's sensitivity to fructose-6-phosphate. rs780095 instead regulates GKRP protein abundance: the G allele sits on a three-SNP haplotype (rs780094-C / rs780095-G / rs780096-G) that drives higher GCKR expression and stronger FOXA2 transcription factor binding²² higher GCKR expression and stronger FOXA2 transcription factor binding
López Rodríguez et al. 2017 confirmed this in 132 heterozygous liver biopsy donors from the Kuopio Obesity Surgery cohort (KOBS); CGG haplotype showed higher H3K27Ac histone marks and FOXA2 binding relative to the TAC haplotype.

The Mechanism

FOXA2 is a hepatocyte-enriched transcription factor that coordinates fasting-state gene programs — including GKRP expression. The rs780095-G allele disrupts a MAFK transcription factor binding motif³³ MAFK transcription factor binding motif
MAF basic leucine zipper transcription factors regulate liver gene expression; rs780095 falls within a predicted MAFK binding site whose integrity differs between the G and A alleles within the intronic enhancer, shifting the regulatory balance toward stronger FOXA2-driven GCKR transcription. More GKRP protein in the hepatocyte means glucokinase spends more time sequestered in the nucleus and less time free in the cytoplasm phosphorylating glucose.

The downstream metabolic consequences follow directly: more GKRP inhibition → less hepatic glucose phosphorylation → slightly higher fasting glucose. Conversely, with glucokinase activity suppressed, less glucose enters the glycolytic pathway, less malonyl-CoA is generated, and hepatic de novo lipogenesis is partially braked. This produces a mirror image of the P446L trade-off: the G allele of rs780095 nudges fasting glucose upward while modestly protecting against GKRP-driven triglyceride overproduction — at least through the expression pathway.

The Evidence

The regulatory role of rs780095 was characterized in a 2017 Genome Medicine study⁴⁴ 2017 Genome Medicine study
López Rodríguez M, Kaminska D, Lappalainen K, Pihlajamäki J, Kaikkonen MU, Laakso M; Genome Medicine 9:63, 2017 using human liver biopsies from 132 individuals heterozygous for the rs780094-rs780095-rs780096 haplotype. In HepG2 hepatoma cells and primary mouse hepatocytes, the CGG haplotype (carrying rs780095-G) showed significantly greater FOXA2-induced transcriptional activity than the TAC haplotype. Allele-specific eQTL analysis in the human liver biopsies confirmed higher GCKR mRNA expression from the CGG haplotype allele.

At the metabolic phenotype level, the closely linked rs780094 and rs1260326 have been studied in tens of thousands of individuals. Orho-Melander et al. 2008⁵⁵ Orho-Melander et al. 2008
Fine-mapping study of the GCKR locus in >45,000 individuals across 12 independent cohorts; Nature Genetics 2008 established that the rs780094-T haplotype (TAC, which carries rs780095-A) is the TG-raising variant, associated with higher triglycerides (P=3×10⁻⁵⁶), lower fasting glucose (P=1×10⁻¹³), and elevated CRP (P=5×10⁻⁵). The ARIC Study (n=14,889)⁶⁶ ARIC Study (n=14,889)
Atherosclerosis Risk in Communities Study; prospective cardiovascular cohort quantified the per-allele effect at −1.93 mg/dl fasting glucose and +0.16 mmol/l triglycerides for the linked rs1260326-T allele.

A meta-analysis of gestational diabetes studies (1,122 women; 267 GDM cases)⁷⁷ meta-analysis of gestational diabetes studies (1,122 women; 267 GDM cases)
Jamalpour et al. 2018, Gene found that the rs780094-C allele (co-inherited with rs780095-G on the CGG haplotype) carries elevated GDM risk (OR 1.32, 95% CI 1.14–1.52), consistent with the glucose-raising effect of the high-GKRP-expression haplotype.

Practical Actions

The actionable interventions for the G allele centre on managing slightly elevated fasting glucose risk. Unlike the closely related rs1260326 P446L effect — where the triglyceride burden drives the main action items — the rs780095 G allele's primary concern is sustained mild elevation of hepatic glucose output through amplified GCK inhibition. Monitoring fasting glucose and HbA1c provides early detection, and dietary strategies that reduce hepatic glycolytic substrate (limiting refined carbohydrates at meals) directly address the elevated GKRP activity. Insulin sensitivity markers (fasting insulin, HOMA-IR) are also worth tracking because reduced hepatic glucose uptake can eventually contribute to compensatory hyperinsulinaemia.

Interactions

rs780095 is in a three-SNP haplotype with rs780094 and rs780096. The closely linked rs1260326 (P446L, r²=0.93 with rs780094) is the functional coding variant that drives the complementary TG-raising/glucose-lowering signal — individuals who carry the P446L T allele likely carry rs780095-A on the same haplotype and have a distinct metabolic profile (lower glucose, higher TG). The GCK promoter variant rs1799884 acts within the same hepatic glucose-sensing network; additive effects on fasting glucose have been reported for GCKR and GCK variants in combination. The PNPLA3 rs738409 G allele compounds hepatic fat risk for carriers of the TG-raising TAC haplotype (rs780095-A side), not the glucose-raising CGG haplotype side.

Before folate — whether from food or supplements — can do its work inside your cells, it has to get through the cell membrane. That job belongs to SLC19A1, also called the reduced folate carrier (RFC1). Without adequate RFC1 function, even normal blood folate levels can mask cellular deficiency. The -43T>C variant (rs914232) sits in the regulatory region just upstream of the SLC19A1 coding sequence and turns down how much of this transporter your cells actually produce.

The Mechanism

Unlike the well-known G80A variant (rs1051266), which changes the transporter's amino acid sequence, rs914232 is a regulatory polymorphism located in the 5'-flanking sequence near the ATG translation start site. This position influences how efficiently the gene is transcribed. Western blot analysis in a clinical study¹¹ Western blot analysis in a clinical study
Chatzikyriakidou et al. Rheumatol Int, 2007 found that the C allele is associated with reduced RFC protein expression levels, meaning cells with this variant simply build fewer transporter molecules. The three SLC19A1 variants -43T>C, 80G>A (rs1051266), and 696C>T (rs3788189) were found to be in strict linkage disequilibrium in that study, suggesting they often travel together and may act in concert.

The Evidence

Evidence for rs914232 is moderate — several small studies with consistent direction but limited statistical power. Chatzikyriakidou et al. 2008²² Chatzikyriakidou et al. 2008
Chatzikyriakidou A et al. Distinct association of SLC19A1 -43T>C with red cell folate levels. Clin Biochem, 2008 studied 64 patients with coronary artery disease and found that the non-wild-type allele of the -43T>C variant was associated with low red cell folate levels. Importantly, that same study showed that MTHFR C677T was associated with low plasma folate rather than red cell folate — two separate compartments — suggesting that SLC19A1 specifically affects folate storage inside red blood cells rather than what circulates in plasma.

In a Korean cohort of 372 colorectal cancer patients, Jang et al. 2014³³ Jang et al. 2014
Jang MJ et al. Polymorphisms of folate metabolism genes and survival of patients with colorectal cancer. Gene, 2014 found that the RFC1 -43CC genotype was associated with favorable overall survival among rectal cancer patients receiving 5-fluorouracil-based chemotherapy — an observation that may reflect altered folate availability affecting treatment pharmacodynamics. In pemetrexed-treated lung cancer patients (n=136), Berghmans et al. 2014⁴⁴ Berghmans et al. 2014
Berghmans T et al. Pharmacogenetics of pemetrexed combination therapy. Pharmacogenomics J, 2014 reported that SLC19A1 rs914232 was among variants associated with overall survival — though these findings require replication in larger cohorts.

Practical Actions

The C allele reduces RFC1 expression, which translates into less efficient folate entry into cells. For most people with the CT or CC genotype, the practical implication is straightforward: methylfolate (5-MTHF) is already in its bioavailable active form and does not need the same degree of transporter-mediated uptake as synthetic folic acid to exert its effects inside cells. Ensuring adequate dietary folate and supplementing with methylfolate rather than folic acid is the primary mitigation.

Interactions

rs914232 acts in concert with the SLC19A1 G80A coding variant (rs1051266), which alters the transporter's amino acid sequence. The two variants are in linkage disequilibrium, so carriers of the C allele at this position often also carry the risk allele at rs1051266. Layered on top of MTHFR variants (rs1801133, rs1801131), combined transport and conversion impairment can further reduce intracellular folate availability. Red cell homocysteine levels are the most clinically relevant biomarker to monitor when both transport and methylation variants are present.

Your immune system constantly chooses between attack strategies. When a cell is infected by a virus or bacteria, T-bet¹¹ T-bet
T-box transcription factor 21 (TBX21) — the master regulator that drives naïve CD4+ T cells to become interferon-gamma-producing Th1 helpers, the immune system's primary response to intracellular pathogens and autoimmune-prone inflammation tells helper T cells to become Th1 fighters, flooding the tissue with interferon-gamma (IFN-gamma) to kill infected cells. When parasites or allergens appear, a different transcription factor (GATA-3) drives Th2 differentiation instead. rs4794067 sits in the TBX21 promoter — the regulatory region that determines how strongly the gene is switched on — and affects how much T-bet a person's immune cells produce.

This variant was first identified in a 2005 Japanese study of aspirin-induced asthma and has since been studied across more than a dozen independent cohorts, including large GWAS datasets totalling millions of genomes. What has emerged is a complex but consistent picture: rs4794067 modulates the overall setpoint of Th1 immune activity in ways that affect susceptibility to autoimmune, inflammatory, and infectious diseases.

The Mechanism

rs4794067 lies approximately 1,993 base pairs upstream of the TBX21 transcription start site on chromosome 17 (GRCh38: chr17:47,731,462), in a region that controls how much TBX21 mRNA is produced in T cells. The C variant allele alters nuclear protein binding at this site.

A functional study by Fyall et al. (2012)²² functional study by Fyall et al. (2012) directly measured immune cell cytokine output in 210 human blood donors stratified by genotype. CC individuals produced significantly less IFN-gamma (p=0.02) and IL-4 (p=0.001) than TT individuals after mitogen stimulation — effects replicated across two independent batches. The CC genotype essentially runs T-bet at a lower dial setting, blunting the Th1 response without fully eliminating it.

The consequence is a shift in Th1/Th2/Th17 balance: C allele carriers mount weaker IFN-gamma-mediated responses, but with less T-bet to suppress Th17 differentiation, they may compensate with elevated IL-17 activity. The periapical lesion study by Colavite et al. (2019)³³ periapical lesion study by Colavite et al. (2019) confirmed this: in C allele carriers, Th17 responses were upregulated at the periapex alongside reduced T-bet/IFN-gamma expression — a mechanistic demonstration of how a single promoter variant reshapes the balance between these two arms of T-cell immunity.

The Evidence

The largest single signal for this variant comes from a 2026 multi-ancestry genome-wide association study by White et al.⁴⁴ genome-wide association study by White et al. analysing ~2.9 million genomes across 19 biobanks. The C allele at rs4794067 emerged as a genome-wide significant risk locus for primary hypothyroidism (beta 0.055, p=8×10⁻⁴²). Thyroid autoimmunity — the dominant cause of primary hypothyroidism — is a Th1/Th17-driven process; altered T-bet-mediated regulation of these pathways is mechanistically consistent with the observed association.

The variant's original discovery context — aspirin-induced asthma — remains biologically instructive. Akahoshi et al. (2005)⁵⁵ Akahoshi et al. (2005) found the C allele significantly associated with aspirin-induced asthma (AIA) susceptibility in Japanese subjects. AIA involves dysregulated arachidonic acid metabolism intersecting with aberrant immune polarisation, and the TBX21 promoter variant appears to modulate this susceptibility in the East Asian context where the C allele is rarer (~11%).

At the tissue level, the T allele shows the opposite pattern. The Cavalla et al. (2015) study⁶⁶ Cavalla et al. (2015) study of 608 Brazilian dental patients found the T allele enriched in chronic periodontitis patients versus gingivitis controls, with T-bet transcripts upregulated in T allele carriers in periodontal tissue. The Li et al. (2024) ankylosing spondylitis study⁷⁷ Li et al. (2024) ankylosing spondylitis study found that the C allele haplotype (rs4794067/C combined with rs11657479/C) increased risk in HLA-B27-positive individuals — a finding in the opposite direction for AS, where Th17 rather than Th1 is the primary effector axis. Together, these studies illustrate that the same promoter variant modulates risk differently depending on which T-cell effector pathway drives the disease.

A 2021 meta-analysis (Wang et al., PMID 33938192⁸⁸ Wang et al., PMID 33938192) synthesised the published association data across autoimmune diseases and concluded that both the T and C alleles confer disease risk in a context-dependent manner, with the T allele specifically associated with elevated autoimmune risk in Asian populations through multiple genetic models.

Practical Implications

For C allele carriers, the dominant theme is blunted Th1-mediated immune regulation, with potential downstream effects on thyroid autoimmunity and susceptibility to aspirin-sensitive airway inflammation. The C allele's large-scale GWAS association with hypothyroidism makes thyroid function monitoring the highest-yield clinical application. The blunted IFN-gamma response may also impair clearance of certain intracellular pathogens — hepatitis C virus persistence was studied in one publication (Zhu et al., 2015) in a Chinese population — though this connection requires further replication.

For TT homozygotes, a more active Th1 response is the norm. While this confers stronger Th1-mediated immunity, it can also predispose to Th1-driven inflammatory pathology in mucosal tissues (periodontitis, periapical lesions) where excess T-bet activity sustains local inflammation.

Interactions

The most studied interaction is between rs4794067 and IFNG rs2069705⁹⁹ IFNG rs2069705 — the interferon-gamma promoter variant. Leng et al. (2016) demonstrated a significant genetic interaction between these two variants in a 3,732-subject Chinese SLE cohort: neither variant independently reached significance for SLE, but their combination was associated with disease risk. This is the canonical "T-bet drives IFN-gamma production" axis reflected in genetics — disrupting either end of the signal chain compounds risk.

rs11657479, another TBX21 intronic variant in strong linkage disequilibrium with rs4794067, has been studied in the same ankylosing spondylitis and uveitis datasets. The haplotype formed by these two variants appears to be the functional unit determining TBX21 expression in specific immune contexts.

Your genome contains a note at position rs58440431 in the CYP2D6 gene — the enzyme responsible for metabolizing approximately 25% of all prescribed medications, from opioid pain relievers to antidepressants to beta-blockers. This intronic variant, located 90 base pairs into intron 6, does not alter the CYP2D6 protein directly. Instead, it acts as a haplotype tag¹¹ haplotype tag
a haplotype tag is a genetic marker in strong linkage disequilibrium with a functional variant — it travels with the functional variant through generations, reliably marking its presence for specific CYP2D6 suballeles, particularly those of the *10 lineage that dominate drug metabolism variation in East Asian populations.

The Mechanism

CYP2D6 star alleles are defined by sets of variants that co-segregate on the same chromosome. The rs58440431 C allele (plus-strand notation; recorded as c.666+90A>G on the coding strand) co-segregates with *10-lineage suballeles (*10, *36, *39) as well as with certain *4 suballeles. These star alleles span a functional spectrum: CYP2D6*10 retains approximately 25–50% of normal enzyme activity²² CYP2D6*10 retains approximately 25–50% of normal enzyme activity
the *10 Pro34Ser substitution (rs1065852) destabilizes the enzyme in the endoplasmic reticulum membrane, while CYP2D6*36 produces a completely non-functional enzyme³³ CYP2D6*36 produces a completely non-functional enzyme
*36 is a rare no-function allele defined in Japanese populations.

The variant itself sits in a region of intron 6 that is in strong linkage disequilibrium with nearby functional changes. Clinical genotyping panels include this position specifically because it improves the accuracy of star allele calling for *10 and related haplotypes — haplotypes that are extremely common in East Asian populations (allele frequency up to 60–68%) but are often underrepresented in genotyping assays designed primarily for European populations.

The Evidence

The clinical relevance of CYP2D6*10 haplotypes — which rs58440431 tags — is well-established. Bradford et al. (2002)⁴⁴ Bradford et al. (2002)
Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics, 2002 documented that *10 is the dominant reduced-function allele in East Asian populations, present at a median frequency of ~41%, making it the single most important CYP2D6 variant to characterize in these populations. In Korean populations specifically, *10 is the most frequent allele at 46.2%⁵⁵ 46.2%
Lee et al. CYP2D6 allele frequencies in Korean population. Biomed Pharmacother, 2018, with *1/*10 and *10/*10 diplotypes accounting for over half of all observed genotype combinations.

CYP2D6 phenotype has direct consequences for tramadol efficacy. In a population-based pharmacokinetic study, Lam et al. (2007)⁶⁶ Lam et al. (2007)
Lam YWF et al. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. J Clin Pharmacol, 2007 found that intermediate metabolizers had 1.3-fold slower tramadol clearance than extensive metabolizers, with the *10 allele present in approximately 40% of the Asian cohort. Reduced clearance translates directly to variable analgesic efficacy and altered adverse effect profiles.

The 2021 joint consensus recommendations for clinical CYP2D6 genotyping⁷⁷ 2021 joint consensus recommendations for clinical CYP2D6 genotyping
Pratt VM et al. Recommendations for Clinical CYP2D6 Genotyping Allele Selection. J Mol Diagn, 2021 explicitly include rs58440431 (recorded as rs2267447) among the core allele-defining SNPs recommended for clinical testing, given its role in accurately identifying *10-lineage haplotypes across multiethnic populations.

Practical Implications

The clinical significance of rs58440431 depends on whether your C allele occurs on a *10, *36, or *39 background — information that requires full haplotype analysis. Without that context, carrying one or two copies of the C allele suggests a meaningful probability of reduced CYP2D6 activity, particularly if you are of East Asian ancestry.

For medications requiring CYP2D6 activation (codeine → morphine; tramadol → O-desmethyltramadol; tamoxifen → endoxifen), reduced activity means reduced therapeutic conversion and potentially inadequate treatment. For medications cleared by CYP2D6 (most antidepressants, some antipsychotics, beta-blockers), reduced activity means drug accumulation and elevated side effect risk.

Interactions

This variant does not act alone. The defining functional variant for *10 is at rs1065852 (Pro34Ser); rs58440431 is an intronic marker that travels with it. Similarly, *36 and *39 suballeles carry additional variants that alter their functional classification. Complete CYP2D6 phenotyping requires assessing all relevant variants on both chromosomes to derive the diplotype and, from that, the predicted metabolizer phenotype. Importantly, drug-drug interactions (phenoconversion) can further reduce CYP2D6 activity — strong inhibitors such as fluoxetine, paroxetine, and bupropion can push intermediate metabolizers into poor metabolizer territory regardless of genotype.

PSEN1¹¹ PSEN1
Presenilin-1: the catalytic subunit of the gamma-secretase complex, a four-protein intramembrane protease complex that cleaves the amyloid precursor protein (APP) and over 100 other substrates is the most frequently mutated gene in familial early-onset Alzheimer's disease. More than 300 pathogenic mutations have been identified; the H163Y substitution is among the best-characterised, having been tracked in a Swedish family for over three decades. Carriers typically develop Alzheimer's disease in their late forties to late fifties — decades before the typical sporadic onset — driven by an altered balance of amyloid-beta peptide species that accelerates plaque formation.

The Mechanism

Gamma-secretase²² Gamma-secretase
A heterotetramer containing presenilin-1 (catalytic), nicastrin, APH-1, and PEN-2, responsible for the final intramembrane cleavage of the amyloid precursor protein. The cleavage site determines whether the shorter, benign Aβ40 or the longer, aggregation-prone Aβ42 is produced normally trims APP through a processive carboxypeptidase mechanism: a long initial Aβ fragment is iteratively shortened before release. Wild-type gamma-secretase preferentially releases Aβ40 as the predominant product, with Aβ42 comprising only ~10% of total Aβ.

The H163Y substitution (c.487C>T; histidine to tyrosine at codon 163) lies within a conserved transmembrane domain critical for coordinating the two catalytic aspartate residues. Fernandez et al. 2014³³ Fernandez et al. 2014
FAD PSEN1 mutations dramatically reduce the carboxypeptidase trimming activity of gamma-secretase, meaning longer Aβ precursors escape without being shortened to Aβ40 — driving up the Aβ42/Aβ40 ratio. J Biol Chem, 2014 demonstrated that this impaired trimming is the primary mechanism by which H163Y and related mutations elevate the Aβ42/Aβ40 ratio. Xia et al. 2015⁴⁴ Xia et al. 2015
PSEN1 knockin mice show loss of gamma-secretase activity, elevated Aβ42/Aβ40, and 22-32% cortical neurodegeneration — supporting a loss-of-function model for FAD pathogenesis. Neuron, 2015 established that the net effect is paradoxical: total Aβ production may fall, yet the shift in species composition accelerates plaque deposition and neurodegeneration.

Downstream consequences in presymptomatic H163Y carriers include decreased plasma Aβ1-38 levels, an altered Aβ1-42/Aβ1-40 ratio trajectory with advancing age, and cortical glucose hypometabolism detectable by PET in the thalamus years before cognitive symptoms appear.

The Evidence

Sherrington et al. 1995⁵⁵ Sherrington et al. 1995
Cloning of the PSEN1 gene on chromosome 14q24.3 and identification of five early-onset FAD mutations in multi-ethnic families including the Swedish H163Y lineage. Nature, 1995 established the causal role of PSEN1 mutations in a subset of aggressive early-onset familial Alzheimer's disease. The H163Y variant has since been classified as Pathogenic in ClinVar (VCV000018130.2) and assigned OMIM allelic variant 104311.0008, with autopsy-confirmed Alzheimer's neuropathology in at least one carrier and documented amyloid burden on PiB-PET in presymptomatic mutation carriers.

Thordardottir et al. 2018⁶⁶ Thordardottir et al. 2018
22-year longitudinal follow-up of two H163Y carrier brothers; average age of symptom onset 51 ± 7 years; one brother remained cognitively intact at age 65 without biomarker evidence of Alzheimer pathology, demonstrating incomplete penetrance. Alzheimers Res Ther, 2018 documented an important nuance: while H163Y is highly penetrant, other genetic, epigenetic, and environmental modifiers can substantially delay or potentially prevent phenotypic expression.

Almkvist et al. 2017⁷⁷ Almkvist et al. 2017
In five autosomal-dominant AD families including PSEN1 H163Y carriers (n=35 carriers, n=44 non-carriers), cognitive divergence began ~10 years before expected clinical onset in episodic memory, executive function, and visuospatial domains. J Int Neuropsychol Soc, 2017 and Johansson et al. 2023⁸⁸ Johansson et al. 2023
Plasma GFAP rises ~10 years before expected onset, followed by p-tau181 and NfL closer to onset; 33 autosomal-dominant AD carriers across mutation types including H163Y. Brain, 2023 together delineate a long presymptomatic window during which biomarker changes accumulate while cognition remains preserved — the most actionable window for intervention.

Practical Actions

For individuals who carry one H163Y allele: the most important step is engaging with a specialist Alzheimer's genetics clinic for longitudinal biomarker monitoring and access to clinical trials. Emerging disease-modifying therapies targeting amyloid (anti-amyloid immunotherapy, gamma-secretase modulators) are now enrolling presymptomatic autosomal-dominant AD mutation carriers, and the benefit-risk profile of these interventions in mutation carriers is categorically different from sporadic late-onset disease. Genetic counselling for first-degree relatives is essential given the 50% per-child inheritance risk.

Pre-symptomatic biomarker monitoring — plasma Aβ42/Aβ40 ratio, GFAP, p-tau181, and NfL — can characterise stage of the pathophysiological cascade and guide trial eligibility and timing decisions. The Dominantly Inherited Alzheimer Network (DIAN) and other registries maintain observational and intervention platforms specifically for autosomal-dominant AD mutation carriers.

Interactions

APOE ε4 (rs429358) modifies age of onset in autosomal-dominant AD families: APOE4 co-carriers tend to have earlier symptom onset and faster cognitive decline than non-APOE4 carriers, while APOE2 may confer partial protection. Whether APOE genotype substantially modifies penetrance of H163Y specifically remains under investigation. Other PSEN1 mutations (including M146V, rs63750066, and I143T) follow the same gamma-secretase loss-of-function mechanism and share the clinical phenotype of early-onset autosomal dominant Alzheimer's disease.

Glucokinase regulatory protein (GCKRP), encoded by GCKR on chromosome 2, acts as a brake on hepatic glucokinase — the enzyme that drives the liver's glucose uptake after meals. The rs780096 variant sits within an intronic enhancer that controls how much GCKRP the liver produces. The G allele of rs780096 anchors the CGG haplotype¹¹ CGG haplotype
Three-SNP cluster spanning rs780094, rs780095, rs780096 — all in strong linkage disequilibrium within a short intronic region of GCKR, which drives higher FOXA2-dependent GCKR transcription in liver cells. The C allele forms the TAC haplotype, which produces less GCKRP and therefore exerts a weaker brake on hepatic glucokinase — contributing to the same glucose-lowering, triglyceride-raising metabolic pattern seen across the GCKR locus.

This is a regulatory variant. Unlike the well-characterized rs1260326 Pro446Leu²² rs1260326 Pro446Leu
Coding missense variant in GCKR that directly reduces GCKRP's sensitivity to fructose-6-phosphate, leaving glucokinase constitutively more active variant that acts by reducing the GCKRP protein's inhibitory function, rs780096 modulates the amount of GCKRP produced. The two variants are not in perfect LD — rs780096 captures an independent layer of GCKR regulation.

The Mechanism

A 2017 Genome Medicine study³³ 2017 Genome Medicine study
López Rodríguez, Kaminska et al., Kaikkonen and Laakso groups, University of Eastern Finland mapped a liver-specific transcriptional enhancer in the GCKR intron containing rs780094, rs780095, and rs780096. The CGG haplotype (G at rs780096) showed approximately twofold higher transcriptional activity in luciferase reporter assays and displayed elevated H3K27Ac histone marks — a hallmark of active enhancer chromatin. FOXA2, a liver-enriched transcription factor critical for hepatic glucose and lipid homeostasis, bound this region in a haplotype-specific manner (CGG > TAC), and CRISPR-based epigenetic activation of the enhancer directly increased endogenous GCKR transcript levels. Human liver biopsies confirmed the CGG haplotype transcribes more GCKR RNA in vivo.

The metabolic logic follows from this: more GCKRP (CGG/G allele) means a stronger brake on glucokinase during fasting, keeping hepatic glucose uptake lower and fasting glucose somewhat higher while reducing the lipogenic flux that generates triglycerides. Less GCKRP (TAC/C allele) means a weaker brake, allowing more glucokinase activity, lower fasting glucose, and — through increased glycolytic flux, malonyl-CoA, and citrate production — elevated de novo lipogenesis⁴⁴ de novo lipogenesis
The liver's conversion of carbohydrate precursors into fatty acids and VLDL-triglycerides.

The four-SNP haplotype incorporating rs1260326 (P446L) paints the full picture: CGGC haplotype (G at rs780096, C at rs1260326 = ancestral Pro446) = maximum GCKRP expression with functional inhibitory protein; TACT haplotype (C at rs780096, T at rs1260326 = Leu446) = reduced GCKRP expression plus a less effective inhibitory protein. These two changes compound each other at the locus.

The Evidence

The primary mechanistic evidence for rs780096's enhancer role comes from López Rodríguez et al. 2017, which used luciferase assays, CRISPR activation, and human liver biopsy data to establish the CGG haplotype's regulatory effect. Effect magnitude⁵⁵ Effect magnitude
The paper reports ~twofold or greater transcriptional activity for CGG vs TAC in HepG2 and primary hepatocytes; FOXA2 co-transfection amplified the difference.

The metabolic phenotype evidence comes from studies of the tightly linked rs780094 and rs1260326, which co-segregate on the same TACT haplotype as the rs780096 C allele. The ARIC Study (n=14,889)⁶⁶ ARIC Study (n=14,889)
Atherosclerosis Risk in Communities Study; Köttgen et al. 2010 quantified per-allele effects of the lipogenic GCKR haplotype: −1.93 mg/dl fasting glucose (P=2.3×10⁻⁷), +0.16 mmol/l triglycerides (P=2.4×10⁻³¹), −0.45 HOMA-IR (P=2.2×10⁻⁹), and +0.56 mg/l CRP (P=1.6×10⁻⁸) in white participants. Sparsø et al. 2008 in 16,853 Danes found fasting triglyceride elevation (P=6×10⁻¹⁴) and reduced insulinaemia⁷⁷ fasting triglyceride elevation (P=6×10⁻¹⁴) and reduced insulinaemia
Linked to the same lipogenic GCKR haplotype with modestly reduced T2D risk.

Gene-diet interactions at the GCKR locus are well documented. Tam et al. 2015⁸⁸ Tam et al. 2015
Study of 660 healthy adolescents; nutrition assessed by food frequency questionnaire found that high fish consumption (rich in omega-3) significantly reduced triglycerides in carriers of the lipogenic GCKR allele. Perez-Martinez et al. 2011⁹⁹ Perez-Martinez et al. 2011
LIPGENE dietary cohort, n=379 metabolic syndrome subjects; plasma omega-3 PUFA measured showed the GCKR risk allele group were "high responders" to omega-3: elevated plasma omega-3 reduced fasting insulin (P=0.019), HOMA-IR (P=0.008), and CRP (P=0.032) selectively in risk allele carriers, suggesting omega-3 supplementation is particularly effective for this genotype.

Practical Actions

The C allele at rs780096 contributes to the same GCKR lipogenic phenotype as the T allele at rs780094 and rs1260326: reduced GCKRP output lowers the brake on hepatic glucokinase, channelling more glucose carbon into fat synthesis. Dietary fructose restriction is the most mechanistically targeted response, since fructose bypasses the rate-limiting phosphofructokinase step and floods the hepatic lipogenic pathway that becomes overactive when GCKRP levels are low. Omega-3 fatty acids (EPA and DHA) suppress VLDL-triglyceride secretion and de novo lipogenesis transcriptionally, and gene-diet interaction data specifically supports their benefit in GCKR risk allele carriers. Fasting triglyceride monitoring provides early warning of worsening lipid profiles before cardiovascular or hepatic risk accumulates.

Interactions

rs780096 is part of a four-SNP haplotype with rs780094, rs780095, and rs1260326 (P446L). The C allele at rs780096 co-segregates with the T allele at rs780094 and rs1260326 on the TACT/lipogenic haplotype. Individuals carrying the C allele here very frequently also carry the T (lipogenic) allele at rs780094 — these variants are not perfectly correlated, but their functional effects compound. The strongest documented gene-gene interaction at this locus is with PNPLA3 rs738409 (G allele): dual carriers of the GCKR lipogenic allele and the PNPLA3 NAFLD allele carry substantially higher hepatic steatosis burden than either alone. The GCK promoter variant rs1799884 interacts with GCKR rs780094 on fasting plasma glucose in Chinese populations; a similar compound effect likely applies to rs780096 C allele carriers.

YKL-40 — named after the amino acids tyrosine (Y), lysine (K), and leucine (L) and its 40-kDa molecular weight — is one of the most clinically informative biomarkers of tissue inflammation. Elevated circulating YKL-40 marks active inflammation in asthma, COPD, rheumatoid arthritis, and several cancers. The protein is encoded by the CHI3L1 gene on chromosome 1q32.1, and how much YKL-40 your body produces is largely predetermined by genetics. The rs4950928 variant in the CHI3L1 promoter is the single strongest genetic determinant of circulating YKL-40 levels yet identified.

The Mechanism

The rs4950928 variant sits 131 base pairs upstream of the CHI3L1 transcription start site (the "-131" in the classical C>G notation used in the literature, which describes the complementary coding strand). This position falls within a transcription factor binding site¹¹ transcription factor binding site
A region of DNA where regulatory proteins attach to control when and how much a gene is read and converted into protein. The common C allele (on the plus strand, ~79% of people) permits higher promoter activity, driving more CHI3L1 transcription and higher secretion of YKL-40 protein by macrophages, neutrophils, and epithelial cells during inflammatory stimulation. The rarer G allele (~21% globally) disrupts the binding site, reducing promoter efficiency and resulting in substantially lower baseline YKL-40 production — roughly half of what CC homozygotes produce.

In childhood birth cohorts involving 2,405 children, Guerra et al.²² Guerra et al.
Guerra S et al. Genetic and epigenetic regulation of YKL-40 in childhood. J Allergy Clin Immunol, 2018 found that methylation at five CpG sites³³ methylation at five CpG sites
DNA methylation is an epigenetic mechanism that adds a chemical tag to gene regulatory regions, typically reducing transcription without changing the underlying DNA sequence partially mediates the rs4950928 genetic effect on YKL-40, suggesting that environmental factors can modulate the gene's output on top of the inherited sequence.

The Evidence

The foundational study appeared in the New England Journal of Medicine in 2008. Ober et al.⁴⁴ Ober et al.
Ober C et al. Variation in the CHI3L1 gene influences serum YKL-40 levels, risk of asthma, and lung function. N Engl J Med, 2008 studied the carefully characterized Hutterite founder population alongside two independent case-control populations of European descent. The rs4950928 variant explained serum YKL-40 variation with extraordinary significance (P=1.1×10⁻¹³). The same variant predicted asthma in combined case-control analysis (P=1.2×10⁻⁵), and correlated with bronchial hyperresponsiveness (P=0.002) and FEV1/FVC ratio (P=0.002).

The dose-response relationship between genotype and YKL-40 was measured precisely by Hansen et al.⁵⁵ Hansen et al.
Hansen JW et al. YKL-40 and genetic status of CHI3L1 in a large group of asthmatics. Eur Clin Respir J, 2015 in 1,827 subjects: CC homozygotes averaged 45 µg/L, CG heterozygotes 32 µg/L, and GG homozygotes 19 µg/L — a more than twofold range driven by a single promoter nucleotide (P<0.0001).

In the Severe Asthma Research Program (SARP), Gomez et al.⁶⁶ Gomez et al.
Gomez JL et al. Genetic variation in CHI3L1 contributes to asthma severity and airway expression of YKL-40. J Allergy Clin Immunol, 2015 found that G allele carriers had lower YKL-40 airway expression and better FEV1% predicted, with this effect being statistically independent of a separate intronic CHI3L1 variant (rs12141494) that also influences asthma severity.

Beyond the airways: in adult cystic fibrosis patients⁷⁷ adult cystic fibrosis patients
Coriati A et al. YKL-40 as a clinical biomarker in adult CF patients. J Cyst Fibros, 2021, CC homozygotes had higher YKL-40, greater dysglycemia, lower lung function, and higher Pseudomonas aeruginosa colonization rates. And in a Chinese hypertension cohort, Xu et al.⁸⁸ Xu et al.
Xu T et al. Association of CHI3L1 gene variants with YKL-40 levels and hypertension incidence. J Cell Mol Med, 2021 found that G-allele carriers had 54% lower hypertension risk in men (OR 0.46, 95% CI 0.23–0.89), suggesting that chronically lower YKL-40 may protect against inflammation-driven vascular disease.

Practical Actions

For the common CC genotype, elevated baseline YKL-40 reflects a higher inflammatory setpoint. If respiratory symptoms are present, serum YKL-40 can serve as a useful monitoring biomarker alongside spirometry. Environmental triggers — allergens, pollutants, cigarette smoke — activate macrophage YKL-40 release and are especially worth avoiding in CC carriers whose baseline is already elevated. Heterozygous CG carriers have a meaningful advantage over CC but not the full protection of GG homozygotes.

For GG carriers, the very low YKL-40 baseline means that standard clinical reference ranges (calibrated to a CC-majority population) may classify their values as anomalously low — which is not pathological but simply reflects their genotype.

Interactions

The intronic variant rs12141494 (CHI3L1 intron 6) independently influences YKL-40 airway expression and asthma severity and was found statistically independent of rs4950928 in conditional analyses (Gomez et al. 2015, PMID 25592985). Together these two variants tag distinct regulatory mechanisms — the promoter (rs4950928) controls baseline circulating YKL-40, while the intronic variant modulates airway tissue expression specifically. The CHI3L1 locus eQTL cluster also includes rs10399931 and rs872129, which contribute additional signal to the YKL-40 quantitative trait locus at chromosome 1q32.1.

Factor V Leiden is the most common inherited thrombophilia¹¹ Thrombophilia: an inherited tendency to form blood clots more easily than normal in people of European descent. Named after the Dutch city of Leiden where it was discovered in 1994 by Bertina et al.²² Bertina et al.
Bertina RM et al. Mutation in Blood Coagulation Factor V Associated with Resistance to Activated Protein C. Nature, 1994, this variant affects the Factor V clotting protein, making it resistant to inactivation by activated protein C (APC), a natural anticoagulant.

The Mechanism

The rs6025 variant causes an arginine-to-glutamine substitution at position 534³³ Amino acid change: arginine to glutamine at position 534 (R534Q), historically reported as R506Q of the Factor V protein. Position 534 is one of the APC cleavage sites - the exact spot where activated protein C normally cuts and inactivates Factor V to prevent excessive clotting. The glutamine substitution prevents APC from cleaving at this site, leaving Factor V active for longer and promoting a hypercoagulable state⁴⁴ Hypercoagulable state: a condition where the blood clots more readily than normal. This variant is classified as pathogenic by ClinVar⁵⁵ ClinVar
VCV000000642 and is found almost exclusively in populations of European ancestry (about 2.4% allele frequency).

The Risk Spectrum

Heterozygous carriers (CT) have a 5-10 fold increased risk⁶⁶ 5-10 fold increased risk
Ridker PM et al. Factor V Leiden and risks of venous thrombosis among men. Lancet, 1995 of venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Homozygous carriers (TT) have a 50-100 fold increased risk. These are lifetime risks that compound with other risk factors like oral contraceptives, pregnancy, surgery, immobility, and long-haul flights.

The Estrogen Interaction

The most critical clinical interaction is with estrogen-containing medications. Estrogen increases several clotting factors and reduces protein S (another natural anticoagulant). For Factor V Leiden carriers, estrogen-containing oral contraceptives multiply the already elevated clotting risk by an additional 30-50 fold⁷⁷ 30-50 fold
Vandenbroucke JP et al. Factor V Leiden and oral contraceptive interaction on VTE risk. Thromb Haemost, 1999. This is why Factor V Leiden testing is recommended before prescribing estrogen-containing contraceptives in women with a personal or family history of blood clots.

Practical Implications

If you are a carrier, the most important actions are: avoid estrogen-containing contraceptives, inform surgeons before any procedure (prophylactic anticoagulation may be needed), stay hydrated and mobile during long flights, and be aware of DVT symptoms (unilateral leg swelling, pain, warmth). Pregnancy requires consultation with a hematologist. Despite the frightening-sounding risk ratios, the absolute annual risk of VTE in heterozygous carriers is still relatively low (about 0.5-1% per year), making this a risk to manage rather than fear.

PSEN1¹¹ PSEN1
Presenilin-1, encoded by PSEN1 on chromosome 14q24.2, is the catalytic subunit of the gamma-secretase complex. Gamma-secretase cleaves the transmembrane domain of the amyloid precursor protein (APP), determining the C-terminal length of the amyloid-beta (Aβ) peptide produced. The relative amounts of longer Aβ42 and Aβ43 versus shorter Aβ40 are central to the amyloid cascade hypothesis of Alzheimer's disease is the most mutation-rich gene in all of medicine, with over 300 pathogenic variants documented in the PSEN1 mutation database. Among these, the Arg278 codon is a hotspot: two independent single-nucleotide substitutions — R278I (c.833G>T, rs63749891 T allele) and R278T (c.833G>C, rs63749891 C allele) — both cause autosomal dominant early-onset Alzheimer's disease. This entry covers both mutations.

Arginine at position 278 lies within transmembrane domain 7 of presenilin-1, a critical structural region for maintaining proper gamma-secretase geometry. The R278I substitution in particular has been used as a reference mutation in mechanistic studies because it produces an unusually severe disruption of enzyme–substrate interactions, making it one of the most thoroughly characterised PSEN1 pathogenic variants at the molecular level.

The Mechanism

Szaruga et al. 2017²² Szaruga et al. 2017
Pathogenic PSEN mutations destabilize the enzyme–substrate complex during gamma-secretase processing of APP, shifting the Aβ peptide length distribution toward longer, more amyloidogenic species. Cell 170:443–456 established the unifying mechanistic framework: normal PSEN1 processively trims Aβ peptides from ~48 amino acids down to predominantly Aβ40, with small amounts of Aβ42 as a byproduct. FAD-causing mutations destabilise the enzyme–substrate complex, causing premature product release at longer lengths and generating disproportionately large quantities of Aβ42 and Aβ43.

Saito et al. 2011³³ Saito et al. 2011
PSEN1 R278I knock-in mice show elevated Aβ43, impaired short-term memory, and accelerated amyloid pathology; Aβ43 aggregates faster and is more neurotoxic than Aβ42; Aβ43 production by other PSEN1 mutations correlates inversely with age of disease onset. Nat Neurosci 14:1023–32 specifically identified Aβ43 — previously understudied — as a potent contributor to pathology in R278I carriers. Heilig et al. 2013⁴⁴ Heilig et al. 2013
Mutant PS1 (R278I) physically interacts with wild-type PS1 to cause dominant-negative inhibition, stimulating Aβ42 and reducing Aβ40 from wild-type presenilin, explaining why a single heterozygous mutation is sufficient for disease. J Neurosci 33:10314–26 extended this model by showing that the mutant allele does not act passively — it actively corrupts the wild-type protein, dramatically amplifying the Aβ42:Aβ40 ratio beyond what the mutant allele alone could produce.

The Evidence

Genotype-phenotype data from large FAD case series converge on a mean age of onset for PSEN1 mutations of approximately 43–45 years (SD ~7 years), with individual mutations accounting for 72% of onset variance, meaning the specific mutation matters more than other genetic background. Ryan et al. 2016⁵⁵ Ryan et al. 2016
Lancet Neurology case series of autosomal dominant FAD; PSEN1 carriers mean onset 43.6 years (SD 7.2); myoclonus in 47%; seizures in ~25%. Lancet Neurol 15:1326–35 documented neurological co-features — myoclonus, seizures — that distinguish PSEN1 carriers from late-onset sporadic Alzheimer's disease.

The R278I variant has a distinctive clinical phenotype first described by Godbolt et al. 2004⁶⁶ Godbolt et al. 2004
Two family members with PSEN1 R278I presenting with progressive language impairment (aphasia) as the initial and dominant symptom, with relative memory preservation; screening for PSEN1 mutations is warranted even in atypical dementia presentations. Neurology 63:1774–5 — a logopenic or frontal-language variant rather than the typical amnestic presentation. A Korean family with the same mutation confirmed the familial segregation pattern (PMID 32174048). The R278T mutation, originally described by Kwok et al. 1997⁷⁷ Kwok et al. 1997
Two novel PSEN1 mutations including R278T in early-onset AD families; R278T associated with co-presenting spastic paraparesis and distinctive large eosinophilic plaques (cotton wool plaques) on neuropathology. Neuroreport 8:1537–40 adds spastic paraparesis as a notable phenotypic feature in some pedigrees.

These pathogenic alleles are essentially absent from population databases — gnomAD v4 shows 0 of 660 alleles in population studies, confirming that virtually no carrier survives to reproductive age without disease manifesting.

Practical Actions

Carriers of one R278I or R278T allele will develop Alzheimer's disease; the principal decisions involve monitoring for early symptom onset, enrolling in prevention and trial registries, and informing first-degree relatives of their 50% inheritance risk. The window for disease-modifying intervention is presymptomatic, making early enrolment in longitudinal studies such as the DIAN (Dominantly Inherited Alzheimer Network)⁸⁸ DIAN (Dominantly Inherited Alzheimer Network)
Multi-site longitudinal study of FAD mutation carriers tracking biomarkers, imaging, and cognition from 20 years before expected symptom onset; mutation carriers are eligible for the DIAN-TU prevention trial the most impactful clinical action available. Tau PET and amyloid PET imaging become abnormal 10–15 years before symptom onset in PSEN1 mutation carriers, providing an observable biomarker window for intervention.

Anti-amyloid immunotherapy (lecanemab, donanemab) approved for early symptomatic sporadic Alzheimer's disease has been tested in DIAN-TU participants; data on PSEN1 mutation carriers specifically continue to evolve. Individuals should discuss eligibility for prevention or treatment trials with a specialist in familial Alzheimer's disease.

Interactions

PSEN1 R278I/R278T acts purely through autosomal dominant haploinsufficiency, so second-allele status at APOE (rs429358 / rs7412) modifies risk trajectory. APOE ε4 carriage accelerates amyloid accumulation and may shift symptom onset earlier even within a PSEN1-mutation background. PSEN2 mutations (e.g. rs63750847 N141I) and APP mutations (rs63750264 V717I) cause the same FAD syndrome but with generally later and earlier onset respectively; compound occurrence of two FAD mutations in one individual is exceedingly rare.